- Home
- AGMH vs ANTX Comparison
AGMH vs ANTX Comparison
Compare AGMH & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- ANTX
- Stock Information
- Founded
- AGMH 2015
- ANTX 2017
- Country
- AGMH Hong Kong
- ANTX United States
- Employees
- AGMH N/A
- ANTX N/A
- Industry
- AGMH EDP Services
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- AGMH Technology
- ANTX Health Care
- Exchange
- AGMH Nasdaq
- ANTX Nasdaq
- Market Cap
- AGMH 42.4M
- ANTX 42.4M
- IPO Year
- AGMH 2018
- ANTX 2022
- Fundamental
- Price
- AGMH $1.45
- ANTX $1.42
- Analyst Decision
- AGMH
- ANTX Hold
- Analyst Count
- AGMH 0
- ANTX 5
- Target Price
- AGMH N/A
- ANTX $3.50
- AVG Volume (30 Days)
- AGMH 146.4K
- ANTX 213.1K
- Earning Date
- AGMH 01-07-2025
- ANTX 11-13-2024
- Dividend Yield
- AGMH N/A
- ANTX N/A
- EPS Growth
- AGMH N/A
- ANTX N/A
- EPS
- AGMH N/A
- ANTX N/A
- Revenue
- AGMH $64,998,081.00
- ANTX N/A
- Revenue This Year
- AGMH N/A
- ANTX N/A
- Revenue Next Year
- AGMH N/A
- ANTX N/A
- P/E Ratio
- AGMH N/A
- ANTX N/A
- Revenue Growth
- AGMH N/A
- ANTX N/A
- 52 Week Low
- AGMH $0.47
- ANTX $0.87
- 52 Week High
- AGMH $2.20
- ANTX $22.22
- Technical
- Relative Strength Index (RSI)
- AGMH 43.02
- ANTX 54.99
- Support Level
- AGMH $1.17
- ANTX $1.32
- Resistance Level
- AGMH $1.64
- ANTX $1.45
- Average True Range (ATR)
- AGMH 0.16
- ANTX 0.08
- MACD
- AGMH -0.01
- ANTX -0.01
- Stochastic Oscillator
- AGMH 40.00
- ANTX 76.00
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.